Navigation Links
Study sheds light on angiogenesis inhibitors, points to limitations, solutions
Date:3/2/2009

A new generation of cancer drugs designed to starve tumors of their blood supply called "angiogenesis inhibitors"succeeds at first, but then promotes more invasive cancer growthsometimes with a higher incidence of metastases, according to a new study in animals. The research clarifies similar findings in other animal studies and is consistent with some early evidence from a small number of clinical trials with cancer patients.

"People have thought that angiogenesis-inhibiting therapy should hinder metastasis, but these studies show this is not necessarily the case," says Gabriele Bergers, PhD, co-author of a paper reporting the study in the March 3, 2009 issue of the journal Cancer Cell. Bergers is an associate professor of neurosurgery and anatomy at the University of California, San Francisco (UCSF).

The scientists urge new studies to determine if the drugs affect tumors in patients as they do in their mouse models of human cancers. They call for preclinical and clinical trials combining angiogenesis-inhibiting drugs with ones targeting the capability for invasion and metastasis. Some treatment strategies already in clinical trials that pair angiogenesis inhibitor drugs with chemotherapy, for example, might gain the first drug's early benefit without triggering subsequent invasion or metastasis, they note.

"The ability of angiogenesis inhibitors to starve tumors rather than poison them has been a true breakthrough," says Douglas Hanahan, PhD, professor of biochemistry and biophysics at UCSF and co-senior author on the paper. "But they are not likely to be a one-stop fix. No cancer drug has yet been found to cure most forms of human cancer. Therapies beat it back, but almost inevitably the cancer develops some form of resistance."

Hanahan and Bergers are both scientists at the UCSF Helen Diller Family Comprehensive Cancer Center.

The other co-senior author of the paper is Oriol Casanovas, PhD , a group lead
'/>"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Thomson Reuters Study Tracks Impact of Recession on Hospitals
2. Insulin drug study shows significant improvements in more than 52,000 diabetic patients
3. Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows
4. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
5. TV viewing before the age of 2 has no cognitive benefit, study finds
6. Kaiser Permanente Study Finds Drinking Wine May Lower Risk of Barretts Esophagus, Precursor to Nations Fastest Growing Cancer, Esophageal Cancer
7. Snowblower Hand Injuries Often Extensive, Study Finds
8. UIC receives $3 million to study prostate cancer risk factors
9. NYU Langone Medical Center study shows that cochlear implant surgery is safe for the elderly
10. Many faces of diabetes in American youth: The SEARCH for diabetes in youth study
11. Atkins Responds to Recent New England Journal of Medicine Weight-Loss Diets Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study sheds light on angiogenesis inhibitors, points to limitations, solutions
(Date:4/1/2015)... 01, 2015 When you’re suffering from back ... finding some relief. Identifying the causes of lingering back or ... cases, the cause of chronic back pain is due to ... diagnosable causes of back pain and offers many possible treatments, ... president of Atlantic Spine Center . , Dr. Liu ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:3/31/2015)... York (PRWEB) April 01, 2015 Bon ... of Charity to the Schervier Nursing Care Center family ... of Mary the Queen in Yonkers which is scheduled ... Jane Iannucelli, SC, president of the Sisters of Charity ... Charity board of directors to place their Sisters at ...
(Date:3/31/2015)... 2015 Cosmetic Town, one of the ... proudly enduring adding news to its site while it ... of plastic surgery and cosmetic medicine better use and ... interconnected sections, the Cosmetic Town community is tingling at ... Cosmetic Town site navigation, News and Blog section, will ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address graduates ... Commencement ceremony on May 9, 2015 and will ... of her eminent career as a nurse, public health ... and senior staff nurse at Brigham and Women’s Hospital ... roles, including President of the American Nurses Association in ...
Breaking Medicine News(10 mins):Health News:Demystifying Facet Joint Syndrome 2Health News:Demystifying Facet Joint Syndrome 3Health News:Demystifying Facet Joint Syndrome 4Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3
... children are to be weighed, measured and interviewed regarding ... //the growing menace of childhood obesity. The Australian Health ... aged between 7 and 15, are either overweight or ... of heart disease and diabetes. Federal Health Minister Tony ...
... surgeon and a researcher at the children hospital of ... dose anti rejection protocol //has appreciably improved the outcomes ... by Rakesh Sindhi, MD, Co-Director of Pediatric Transplantation, and ... new protocol reduces drug doses and eliminates steroids altogether ...
... up with a new preventive strategy to fight childhood obesity.// ... concern for both the parent and the society. In the ... a program in Meade County, Ky to fight childhood obesity. ... researchers are planning to launch the new program among the ...
... According to the scientist from the Victorian Breast Cancer Research ... have undergone some mutation give rise to the most aggressive ... Hall Institute researchers were working on mouse models when they ... for the female hormones oestrogen or progesterone. This characteristic is ...
... revealed that many popular breakfast cereals contain high levels of ... brands of cereals that were checked for sugar, salt and ... than three-quarters had a high level of sugars, while a ... had high level of saturated fat. ...
... recent announcements by Health Minister, Tony Abbott, to tackle ... has failed to impress AMA President Mukesh// Haikerwal. The ... so that problem can be tackled more effectively. ... new ministerial taskforce for an anti-obesity campaign involving industry ...
Cached Medicine News:Health News:Low Dose Anti Rejection Protocol Helps Intestinal Transplant Recipients 2Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
(Date:4/1/2015)... , April 1, 2015 Valeant Pharmaceuticals International, ... today announced the expiration of the tender offer (the ... to purchase all of the outstanding shares of Salix ... price of $173.00 per share in cash, without interest, ... midnight, Eastern time, on April 1, 2015.  Valeant expects ...
(Date:4/1/2015)... Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: ... raw materials used in the manufacture of traditional Chinese medicine ... financial results for the three- and twelve-months ended December 31, ... 31,Twelve Months Ended December 31, 2014 , 2013 ... $686,669 , $998,934 $4,043,290 , ...
(Date:3/31/2015)... March 31, 2015 Neurocrine Biosciences, Inc. (Nasdaq: ... into an exclusive collaboration and licensing agreement for the ... Japan and other select Asian ... Tanabe intends to initially develop NBI-98854 in ... disease and tardive dyskinesia. Neurocrine retains full commercial rights ...
Breaking Medicine Technology:Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 2Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 4Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 5Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 6Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 7Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 8Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 9Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 10Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 11Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
... Penilab IV and the Penilab V have an exceptionally ... 1060 is similar to the Model 1061 shown below, ... be added later. The Penilab V has a ... the accessories you'll need to get started. Latex ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... MRI-Compatible Anesthesia System is perfect for larger surgery ... type of anesthetic agent. , ,The Integra ... its wider stance, has a larger work area. ... is utilized in both the Integra I and ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
Medicine Products: